161

So12 Molecular Therapies - Neuroprotection
Symposiumof the section DOG-genetics, DOG 2020 Online

So12 Molecular Therapies - Neuroprotection
Symposiumof the section DOG-genetics, DOG 2020 Online

 Zum Kalender hinzufügen
 Veranstaltung teilen
 Zur Merkliste hinzufügen
Datum
11.10.2020, 13:30 - 14:15
Sprache
Englisch
Gebühren ab
gebührenfrei
Veranstalter
DOG - Deutsche Ophthalmologische Gesellschaft e.V.
Organisator

INTERPLAN AG
Congress, Meeting & Event Management AG
Landsberger Straße 155
DE - 80687 München
Tel.: +49 (0)89 548 234 35
Tel.: +49 (0)89 548 234 0
Fax: +49 (0)89 548 234 43
Fax: +49 (0)89 548 234 44

Recent advances in the understanding of the pathogenesis of retinal diseases have paved the way for the development of new therapeutic approaches. Protein homeostasis has been shown to be important in keeping cellular mechanisms functioning, and once this homeostasis is severely affected, survival of the cells is no longer granted, independent of the underlying pathology.
  • Basisinformation
    Datum
    11.10.2020, 13:30 - 14:15
    Sprache
    Englisch
    Gebühren ab
    gebührenfrei
    Veranstalter
    DOG - Deutsche Ophthalmologische Gesellschaft e.V.
    Organisator

    INTERPLAN AG
    Congress, Meeting & Event Management AG
    Landsberger Straße 155
    DE - 80687 München
    Tel.: +49 (0)89 548 234 35
    Tel.: +49 (0)89 548 234 0
    Fax: +49 (0)89 548 234 43
    Fax: +49 (0)89 548 234 44

  • Programm

    Organisator/Vorsitzender: Knut Stieger | Gießen
    Vorsitzender: Marius Adler | Dresden

    One important pathway that has re-entered center stage is therefore neuroprotection for which several newly identified regulators of cell survival and viability have been identified. Preclinical studies are promising and the start of first in-human trials are likely to follow soon. The approval of Luxturna gene therapy in Europe in November 2018 has resulted in the treatment of a number of patients all over Europe, but has also shown that legislation and institutional support for this new class of medication can be important hurdles.

     

    So12-01
    13:30
    13:45

    Proteome centric target discovery for photoreceptor protection: the p97/VCP story

    Due to high production rates in visual pigment and high metabolic activity photoreceptor cells are especially vulnerable to defects in protein homeostasis. The ATPase Valosine Containing Protein (p97/VCP) acts as a protein quality control checkpoint of membrane proteins and binds to rhodopsin before the protein is released from the ER towards plasma membrane localization. Inhibiting VCP ATPase activity pharmacologically, we have generated evidence for a strong and long-lasting rescue of degenerating rod photoreceptors in the RhoP23H transgenic rat suggesting VCP as a target to treat autosomal dominant RP. Protection correlates with restoration of physiological rhodopsin trafficking to rod outer segments, improved rod OS ultrastructure and an improved ERG after intravitreal injection of the inhibitors.

    		 Marius Ueffing | Tübingen

    So12-02
    13:45
    14:00

    Retinoic acid receptor inhibitors in retinal diseases

    		 Richard Kramer | Berkeley/USA

    So12-03
    14:00
    14:15

    Proteostasis in retinal disease

    		 Ronald Roepman | Nijmegen/NL
  • Gebühren
    Fachärzte/-innen
    Gebühren ab
    120,00 EUR
    Ärzte/-innen in Weiterbildung
    Gebühren ab
    120,00 EUR
    Studenten/-innen
    Gebühren ab
    gebührenfrei
    The full congress is free for students and PhD students.
  • Buchung / Anmeldung

    Registration required. Please contact the organizer for further information.

  • Zertifizierung
    Keine Zertifizierung beantragt

Veranstaltung teilen

Kontakt zu EYEFOX

+49 (30) 4036 422 - 0

info@eyefox.com